Gliclazide + Metformin Tablets(ir) Generics - Manufacturers & Suppliers
Glizid-M, Glyciphage-G(US & EU)
| Product/Composition:- | Gliclazide + Metformin Tablets(IR) |
|---|---|
| Strength:- | Gliclazide 80 mg + Metformin 500 mg |
| Form:- | Tablets(IR) |
| Reference Brands:- | Glizid-M, Glyciphage-G(US & EU) |
| MOQ | As per the manufacturer batch size |
| Get Quote Send Enquiry on WhatsApp | |
Gliclazide stimulates pancreatic β-cells to release insulin, while Metformin reduces hepatic glucose production and improves insulin sensitivity. Together, they offer synergistic glucose control in type 2 diabetes. This dual-action therapy improves HbA1c levels, reduces fasting/postprandial glucose, and delays diabetes progression. Ideal for patients needing intensified glycemic control with oral agents.
Gliclazide + Metformin 80/500 mg immediate-release tablets are approved and marketed in several European and Asian countries, especially for Type 2 Diabetes Mellitus. This fixed-dose combination helps improve glycemic control by combining a sulfonylurea (Gliclazide) with a biguanide (Metformin). While widely available in the EU under brands like Glizid-M and Diamicron-M, this formulation is not approved by the U.S. FDA, as Gliclazide is not marketed in the U.S. Regulatory authorities in the EU assess it under EMA or national frameworks for fixed-combination antidiabetics. Pharmatradz.com lists reputable API manufacturers and global B2B sources for Gliclazide + Metformin IR tablets.